NCT03486301 - BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2024

Conditions

Tumor, Solid

Interventions

DRUG

BDB001 (EIK1001)

BDB001 (EIK1001) is an immunotherapy agent.

DRUG

Pembrolizumab

Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Trial Locations (5)

34230

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, Nashville

78229

NEXT Oncology, San Antonio

South Texas Accelerated Research Therapeutics (START), San Antonio

07960

Atlantic Health, Morristown